Comprehensive Clinical Genetics, Molecular and Pathological Evaluation Efficiently Assist Diagnostics and Therapy Selection in Breast Cancer Patients with Hereditary Genetic Background
International Journal of Molecular Sciences · 22.11.2024 · 25 (23) · 12546
DOI: 10.3390/ijms252312546 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.11.2024. Verfasst von Petra Nagy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and The National Tumour Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Centre, Ráth György…. Hauptthemen laut MEDLINE: Genetic Testing, Breast Neoplasms, Genetic Predisposition to Disease, Hereditary Breast and Ovarian Cancer Syndrome. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Development and Innovation Office, New National Excellence Program of the Ministry of Human Capacities, Hungarian Academy of Sciences.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Using multigene panel testing for the diagnostic evaluation of patients with hereditary breast and ovarian cancer (HBOC) syndrome often identifies clinically actionable variants in genes with varying levels of penetrance. High-penetrance genes (BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53) inform specific clinical surveillance and therapeutic decisions, while recommendations for moderate-penetrance genes (ATM, BARD1, BRIP1, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, NF1, RAD51C, RAD51D) are more limited. A detailed disease history, including pedigree data, helps formulate the most appropriate and personalised management strategies. In this study, we evaluated the clinical benefits of comprehensive hereditary cancer gene panel testing and a pre-sent questionnaire in Hungarian patients with suspected HBOC syndrome. We prospectively enrolled 513 patients referred for HBOC testing. Of these, 463 met the genetic testing criteria, while 50 did not but were tested due to potential therapeutic indications. Additionally, a retrospective cohort of 47 patients who met the testing criteria but had previously only been tested for BRCA1/2 was also analysed. Among the 463 patients in the prospective cohort, 96 (20.7%) harboured pathogenic/likely pathogenic (P/LP) variants—67 in high-penetrance genes and 29 in moderate-penetrance genes. This ratio was similar in the retrospective cohort (6/47; 12.7%). In patients who did not meet the testing criteria, no mutations in high-penetrance genes were found, and only 3 of 50 (6%) harboured P/LP variants in moderate-penetrance genes. Secondary findings (P/LP variants in non-HBOC-associated genes) were identified in two patients. In the prospective cohort, P/LP variants in BRCA1 and BRCA2 were the most prevalent (56/96; 58.3%), and the extended testing doubled the P/LP detection ratio. Among moderate-penetrance genes, five cases (three in the prospective and two in the retrospective cohorts) had P/LP variants in Lynch syndrome-associated genes. Further immunohistochemistry analysis of breast tumour tissues helped clarify the causative role of these variants. Comprehensive clinical and molecular genetic evaluation is beneficial for the diagnosis and management of patients with P/LP variants in hereditary tumour-predisposing genes and can serve as a basis for effective therapy selection, such as PARP inhibitors or immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Genetics and The National Tumour Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Centre, Ráth György u. 7-9, 1122 Budapest, Hungary.
- HUN-REN-SE Hereditary Tumours Research Group, Hungarian Research Network, Nagyvárad tér 4, 1089 Budapest, Hungary.
- Department of Laboratory Medicine, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.
- Department of Oncology Biobank, National Institute of Oncology, Comprehensive Cancer Centre, Ráth György u. 7-9, 1122 Budapest, Hungary.
ORCID-Profile: Petra Nagy, Anikó Bozsik, Attila Patócs, Henriett Butz
Förderung
- National Research Development and Innovation Office
- New National Excellence Program of the Ministry of Human Capacities
- Hungarian Academy of Sciences
- National Research, Development and Innovation (NRDI) Office
- Hungarian Thematic Excellence Program
- NRDI
- Bolyai Research Fellowship of the Hungarian Academy of Sciences
- NRDIO
Zitieren
APA
Nagy, P., Papp, J., Grolmusz, V. K., Bozsik, A., Pócza, T., Oláh, E., Patócs, A., & Butz, H. (2024). Comprehensive Clinical Genetics, Molecular and Pathological Evaluation Efficiently Assist Diagnostics and Therapy Selection in Breast Cancer Patients with Hereditary Genetic Background. International Journal of Molecular Sciences, 25(23), 12546. https://doi.org/10.3390/ijms252312546
Vancouver
Nagy P, Papp J, Grolmusz VK, Bozsik A, Pócza T, Oláh E, et al. Comprehensive Clinical Genetics, Molecular and Pathological Evaluation Efficiently Assist Diagnostics and Therapy Selection in Breast Cancer Patients with Hereditary Genetic Background. International Journal of Molecular Sciences. 2024;25(23):12546. doi:10.3390/ijms252312546
BibTeX
@article{Nagy2024,
author = {Nagy, Petra and Papp, János and Grolmusz, Vince Kornél and Bozsik, Anikó and Pócza, Tímea and Oláh, Edit and Patócs, Attila and Butz, Henriett},
title = {Comprehensive Clinical Genetics, Molecular and Pathological Evaluation Efficiently Assist Diagnostics and Therapy Selection in Breast Cancer Patients with Hereditary Genetic Background},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {23},
pages = {12546},
doi = {10.3390/ijms252312546}
}
EUVIMED